Price of Multiple Sclerosis Disease Modifying Therapies Keeps Creeping Up
Disease modifying therapies (DMTs) for multiple sclerosis (MS) have a significant positive impact on patient outcomes but are often expensive. A recent report by GlobalData finds that prices for MS DMTs are on a steady increase, with drugs like Tysabri by biogen or Gilenya by Novartis increasing by 12%. This impacts patients, according to many experts.
Using Real-World Data for Patients with Multiple Sclerosis: A New Machine Learning Model for the Expanded Disability Status Scale (EDSS)
Multiple sclerosis (MS) is a chronic illness in which the body’s immune system attacks myelin, the substance that surrounds [...]
ISPOR Value in Health Regional: Cost of Multiple Sclerosis in Iran
Multiple sclerosis (MS) is a chronic illness characterized by an autoimmune attack on the central nervous system that is associated [...]
Biogen Settles MS Kickback Suit for $900M
Biogen has settled a whistleblower suit regarding kickbacks for its line of multiple sclerosis (MS) drugs. The company was sued for allegedly paying clinicians kickbacks when they prescribed its drugs Tecfidera, Tysabri, and Avonex. The settlement comes as competition from Novartis and Ocrevus closes in on Biogen’s MS drugs
New Data Shows Bristol Meyers Squib’s Zeposia Improves Cognitive Outcomes in Multiple Sclerosis Patients
Results from Bristol Meyers Squib’s (BMS) Phase 3 DAYBREAK and SUNBEAM trials show that Zeposia helps improve and preserve cognitive [...]
ICER Will Assess Value and Effectiveness of Multiple Sclerosis Treatments
The Institute for Clinical and Economic Review (ICER) will perform value and effectiveness assessments on several drugs for multiple sclerosis. [...]
Virus Strongly Linked to Multiple Sclerosis in New Study
Infection with the Epstein-Barr virus dramatically raised the risk of developing multiple sclerosis (MS), according to a newly-published paper in [...]
Biogen, UPMC Health Plan Contract Links PROs to Drug Reimbursement for Multiple Sclerosis
Biogen and UPMC Health Plan have signed off on a value-based contract that would link reimbursement to patient-reported outcomes for [...]
